The University of Tennessee Research Foundation (UTRF) has entered into a licensing agreement with CytoSen Therapeutics, Inc. for commercial rights to use the K-562 cell lines to produce an innovative natural killer (NK) cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Unlike other cell therapies, this approach has the potential to be used as a treatment component for many types of cancer.
License Agreement
Peroxygen Systems, Inc. Secures Licensing Agreement with UTRF
Knoxville start-up Peroxygen Systems Inc., winner of the 2016 “Tennessee Venture Challenge,” has entered into a licensing agreement with the University of Tennessee Research Foundation (UTRF) to commercialize the onsite hydrogen peroxide production process. Since winning the April TVC competition, the start-up has pilot-tested a medium-size prototype that produced a 50 percent savings over the (read more)
2016 UTRF Innovation Awards (Knoxville)
[tribulant_slideshow gallery_id=”18″] 2016 Wheeley Award Recipients: Jayne Wu and Shigetoshi Eda Click here to read 2016 Wheeley Award article. Patent Plaque Recipients: Raul Almeida Lawrence Anovitz J. Doug Birdwell Feng Chen Lloyd Davis J. Lannett Edwards Richard Evans Kenneth Gilbert George Guiochon (Posthumous Recognition) Howard Hall Roger Horn Sally Horn David Icove David Jenkins Stephen Kennel (read more)